JAZZ PHARMACEUTICALS, INC.

Lobbying for JAZZ PHARMACEUTICALS, INC.

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 17, 2025

Expenses

$410,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 3

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 946
ORPHAN Cures Act

Lobbying activity 1

Pharmacy

FDA regulation of CBD FDA Rare Disease PPRV program/reauthorization Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Issues related to the regulation of intoxicating hemp Most Favored Nation drug pricing Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act HR 946: Orphan Cures Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.